The fundraising landscape for healthcare and life science companies has changed dramatically over the past several years. Entrepreneurs and business owners in these industries need to look toward emerging categories of investors to provide the funding that was historically serviced by venture capital firms (VC’s). Corporate venture funds, angels and angel networks, government agencies, and foundations are all actively investing in these sectors and represent newer, non-traditional avenues for raising capital. However, the latest growing trend is the participation of family offices.(more…)
"Working with life science companies is not like serving other industries. There are myriad legal and financial eccentricities - accounting for multiple financing sources makes accounting especially complex, for instances and protecting intellectual property is key. Early-stage companies may need their hand held as they focus on the science and outsource everything else." San Diego Business Journal
Los Angeles, CA April 24, 2018 — Objective Capital Partners, a leading middle market investment banking firm, is pleased to announce that it served as the exclusive financial advisor to StudyKIK LLC, a rapidly-growing healthcare IT company, on its acquisition by Kinderhook Industries LLC.
“Matt and his team have done a remarkable job in creating a leading patient recruiting platform which is having an enormous impact by making it dramatically more efficient for clinical trial companies to find and engage the high-fit trial volunteers they need to bring new and innovative treatments to market,” said Channing Hamlet, Managing Director of Objective Capital Partners. “We are privileged to have had this opportunity to help StudyKIK and couldn’t be more excited about the future of the company.”(more…)
San Diego Business Journal Health Care Heros Award
San Diego, March 1, 2018 – The San Diego Business Journal’s 2018 Health Care Heroes Awards chose Objective Capital Partners’ David H. Crean, Ph.D. from among the finalists to receive the Health Care Hero Award for Company Executive for his role in healthcare innovation and support.
Leading Objective Capital Partners’ Life Sciences & Healthcare Investment Banking Practice, David leverages more than 20 years of life sciences R&D and corporate development experience. In his Managing Director role, David helps companies secure growth capital, establish strategic partnerships, and achieve exit transactions.(more…)
The Alliance of Merger & Acquisition Advisors® (AM&AA)
San Diego, January 30, 2018 — Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., Managing Director of the firm’s thriving Life Sciences and Healthcare practice, has been selected as the winner of the 2017 Thought Leader of the Year Award by The Alliance of Merger & Acquisition Advisors® (AM&AA).
The AM&AA recognized that “David’s thought leadership is materially expanding the investment banker’s role in serving life sciences companies and providing these companies with a highly attractive, non-diluting alternative to hard-to-secure venture capital financing.”
“We are observing life sciences and healthcare companies increasing engaging specialized investment banking teams with deep industry experience to gain a strategic advantage,” said Trever Acers, Managing Director at Objective Capital Partners. “Specialized professionals such as David and his team members at Objective Capital are engaged by experienced Life Sciences executives to significantly improve the value, probability and speed of their M&A, strategic partnering, and growth capital objectives. David is at the forefront of this change, leveraging his decades of industry experience with best-in-class investment banking capabilities to provide CEO with highly actionable strategic guidance."(more…)
News Announcement, David H. Crean, Healthcare, Life Sciences, Middle Market, objective capital partners, Alliance of M&A Advisors, Alliance of Mergers & Acquisitions Advisors, Thought Leader, Thought Leader of the Year
San Diego, December 12, 2017 — Objective Capital Partners, a middle market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, has been selected as top five national finalist for the 2017 Thought Leader of the Year Award by The Alliance of Merger & Acquisition Advisors® (AM&AA). For more information on the Award and the Finalists, please visit http://www.amaaonline.com/thought-leader-of-the-year/(more…)
Objective Capital’s David H. Crean to be Guest Panelist at ACG Orange County's CEO Signature Event on November 15, 2017
San Diego, November 6, 2017 — Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, will be a guest panelist speaker at ACG Orange County’s CEO Signature Event entitled SoCal Capital Summit on November 15, 2017. Dr. Crean and the fellow panelists will address M&A Healthcare Trends and Opportunities. He will be joined by Greg Cunniff, CFO, NVISION Eye Centers, and Steven Shill, Partner and National Healthcare Practice Leader at BDO.(more…)
Objective Capital Partners Acted as Financial Advisor to MID
San Diego, CA- August 21, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A, healthcare & life sciences and valuation advisory services, is pleased to announce the successful closing of one of its advisory engagements with Minimally Invasive Devices (MID), privately-held medical device and market leading laparoscopic surgery solutions company, upon its acquisition by Cagan McAfee Capital Partners and seasoned investor/operator, Myles Sherman of Austin, TX. Objective Capital Partners acted as financial advisors to MID.(more…)
FloShield, Laird Cagan, Mergers & Acqusitions, Minimally Invasive Devices, Cagan McAfee Capital Partners, Healthcare, Laparoscopic Surgery, Life Sciences, Myles Sherman, objective capital partners, Business Sale, Uncategorized, Wayne Poll
Start-up and Emerging Companies to Present at BIO2017
San Diego, CA- June 12, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle-market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as a Judge for company finalists during live presentations as part of BIO 2017 Start-Up Stadium on June 20-22, 2017 in San Diego, CA. As the world’s largest biotechnology event, the BIO International Convention provides several specialized opportunities geared towards start-up and emerging companies. The Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, and BIO attendees.(more…)
Panel Discussion on Life Sciences Transactions, Research Collaborations, and Licensing Models to be presented on June 17, 2017
San Diego, CA- May 31, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as a panel member and address legal professionals at the 5th Annual World Life Sciences Conference, June 16–17, 2017 at the Westin San Diego Gaslamp Quarter, San Diego, CA. The conference is presented by the International Bar Association (IBA), a global voice for the legal profession. The event will feature dynamic roundtable sessions covering the hottest topics and the latest developments from across the different sectors of the Life Science Industry.(more…)
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.